Japan regulators review the Biomet-Zimmer merger for anti-trust

Japan probes Biomet-Zimmer merger (MassDevice) Your Dashboard for the Zimmer-Biomet Merger  Japanese regulators are the latest to probe the pending merger of Biomet and Zimmer to make sure it meets anti-trust muster. Japanese anti-trust regulators are the latest to scrutinize the pending merger of Zimmer (NYSE:ZMH) and Biomet, joining agencies in the U.S. and Europe that are already looking at the deal. The Japan Fair Trade Commission said Sept. 3 that it's opening an investigation into the $13.35 billion mega-deal between the orthopedic device giants, 1st announced in April. "With the knowled...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top